8-K
filed May 17, 2024, 7:59 PM ET
ticker CTMX
CIK 0001501989
other
confidence high
sentiment neutral
materiality 0.40
Stockholders approve doubling authorized common stock to 300M shares
CytomX Therapeutics, Inc.
- Charter amendment to increase authorized common stock from 150M to 300M shares approved with 42.7M for, 3.2M against.
- Class III directors Ashworth, Meyers, and Gilbert each elected with >24M votes for; broker non-votes of 17.6M.
- Ratification of Ernst & Young as auditor for FY2024 passed with 46.5M votes for.
- Advisory vote on executive compensation approved with 27.4M for, 1.9M against, 17.6M broker non-votes.
- All four stockholder proposals at May 15 Annual Meeting were approved.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
CytomX Therapeutics, Inc.: Increased authorized shares of common stock from 150,000,000 to 300,000,000 shares (effective 2024-05-17).
- Change
- charter amendment
- Effective
- 2024-05-17
Exact text from the filing
On May 17, 2024, CytomX Therapeutics, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an Amended and Restated Certificate of Incorporation reflecting an amendment to increase the authorized number of shares of the Company’s common stock from 150,000,000 to 300,000,000 shares (the “Charter Amendment”).
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.98
CytomX Therapeutics, Inc. shareholders approved Advisory vote on executive compensation at the 2024-05-15 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2024-05-15
Exact text from the filing
Proposal 4. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC. FOR AGAINST ABSTAIN BROKER NON-VOTES 27,396,411 1,905,835 61,704 17,554,723
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.98
CytomX Therapeutics, Inc. shareholders approved Amendment to increase authorized shares of common stock from 150,000,000 to 300,000,000 at the 2024-05-15 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2024-05-15
Exact text from the filing
Proposal 3. The Company’s stockholders approved of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 shares to 300,000,000 shares. FOR AGAINST ABSTAIN 42,707,436 3,211,496 999,741
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.98
CytomX Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm at the 2024-05-15 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2024-05-15
Exact text from the filing
Proposal 2. The Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. FOR AGAINST ABSTAIN 46,522,474 369,346 26,853
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
CytomX Therapeutics, Inc. shareholders approved Election of Class III directors at the 2024-05-15 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2024-05-15
Exact text from the filing
Proposal 1. The Company’s stockholders elected the Class III director nominees below to the Company’s Board of Directors to hold office until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or the earlier of their death, resignation or removal. NOMINEE FOR AGAINST ABSTAIN BROKER NON-VOTES Alan Ashworth, Ph.D., FRS 28,770,373 514,091 79,486 17,554,723 James R. Meyers 28,970,141 324,310 69,499 17,554,723 Halley Gilbert 24,008,423 5,271,685 83,842 17,554,723
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.